Mylan NV (MYL)

39.33
NASDAQ : Health Technology
Prev Close 39.33
Day Low/High 0.00 / 0.00
52 Wk Low/High 29.39 / 47.82
Avg Volume 4.37M
Exchange NASDAQ
Shares Outstanding 515.45M
Market Cap 20.39B
EPS 1.30
P/E Ratio 29.36
Div & Yield N.A. (N.A)

Latest News

A Mom's Mother's Day Message to Wall Street: 'Enough Already'

A Mom's Mother's Day Message to Wall Street: 'Enough Already'

A Mother's Day message to Wall Street. Why are women and mom's still lagging when it comes to leadership and pay parity. Yes. it's 2018. Watch videos, listen to podcasts.

Mylan First-Quarter Revenue Misses Estimate Amid Lower Sales of Branded Product

Mylan First-Quarter Revenue Misses Estimate Amid Lower Sales of Branded Product

The EpiPen maker saw a 19% drop in North America net sales due in part to lower sales of branded products.

How to Play Trump's New 'War' With Iran: Market Recon

How to Play Trump's New 'War' With Iran: Market Recon

While the move higher for crude prices late Tuesday took the energy sector with it, defense and aerospace names saw benefit as well.

Mylan Becomes #20 Most Shorted Nasdaq 100 Component, Replacing QVCA

The most recent short interest data has been released for the 04/13/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Weekly Roundup

A strong Friday failed to keep markets in positive territory.

Teva Shows Progress on Restructuring But Investors Want More

Teva Shows Progress on Restructuring But Investors Want More

The Israel-based drugmaker reported first-quarter numbers that surpassed analysts' expectations but Wall Street wants to see more.

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

The tough news keeps coming at the generic drug company, which announced last week it was considering putting itself up for sale. Now the Justice Department wants a chat.

Mylan Presents Equivalence Data On Glatiramer Acetate Compared To Copaxone® At American Academy Of Neurology 70th Annual Meeting

Three posters highlight Mylan's rigorous Glatiramer Acetate development program

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.

Mylan's Stock Gets Bump After Investor Day

Mylan's Stock Gets Bump After Investor Day

Following Wednesday's event, Leerink analyst Ami Fadia said she is 'incrementally more positive' on the drugmaker's pipeline and diversified business model and moved her rating to outperform.

Mylan Spotlights Diversification at Investor Day

Mylan Spotlights Diversification at Investor Day

The drug company generates about 60% of revenue outside the U.S.

American Medical Association Rejects Idea of Time Limits on Opioid Scripts

American Medical Association Rejects Idea of Time Limits on Opioid Scripts

While more than half the states in the U.S. have passed time limits on opioid prescription as a way to battle the epidemic, the AMA says that should be left up to the doctor and patient.

Biosimilar Pipeline Among Areas of Shareholder Focus at Mylan's Investor Day

Biosimilar Pipeline Among Areas of Shareholder Focus at Mylan's Investor Day

The pharmaceutical firm will conduct its investor day in New York City on April 11.

Mylan Introduces Symfi™ Triple Combo Once-Daily HIV Treatment In The U.S.

Mylan Introduces Symfi™ Triple Combo Once-Daily HIV Treatment In The U.S.

- Approval complements growing portfolio of cost-saving antiretroviral medications available to patients in the U.S., including recently announced Symfi Lo™ and Cimduo™

Mylan Adds To Growing Oncology Portfolio With Launch Of Generic Mutamycin® Injection

Mylan Adds To Growing Oncology Portfolio With Launch Of Generic Mutamycin® Injection

- Mitomycin for Injection is available to Mylan's hospital and other institutional customers -

Allergan CEO: We Are Looking at All Options to Create Shareholder Value

Allergan CEO: We Are Looking at All Options to Create Shareholder Value

Brent Saunders spoke at the Barclays healthcare conference, a few weeks after Mylan and Revance Therapeutics said they were teaming up on a proposed biosimilar of Allergan's Botox.

Generic Drug Sector Shifting With Legal Pressure, Changes at FDA

Generic Drug Sector Shifting With Legal Pressure, Changes at FDA

A massive price-fixing lawsuit brought by 45 states against a group of generic drug producers as well as a changing of the guard at the Food and Drug Administration may lead to changes in the generic drug sector.

Mylan Breaks Out Amid Generic Malaise; Target Shorts Rejoice -- ICYMI

Mylan Breaks Out Amid Generic Malaise; Target Shorts Rejoice -- ICYMI

Here's what you need to know now for Tuesday, March 6.

Mylan Shares Surge as Analyst Says It's Poised to Gain Share From Rivals

Mylan Shares Surge as Analyst Says It's Poised to Gain Share From Rivals

Morgan Stanley analyst David Risinger is upbeat about the drugmaker's generic drug growth prospects in the U.S.

Senator Asks Drug Companies What They'll Do With Extra Cash From Big Tax Cut

Senator Asks Drug Companies What They'll Do With Extra Cash From Big Tax Cut

Senator Tina Smith wants some answers from a group of Big Pharma companies about how the new cash flowing from the corporate tax break will be spent.

Trimming Allergan

This is the exact type of strength we are looking for and recoups some of the cash we used earlier this morning.

Weekly Roundup

Volatility picked up this week due to news from Washington.

Mylan To Introduce Two New Cost-Saving HIV Combination Treatments In The U.S.

Mylan To Introduce Two New Cost-Saving HIV Combination Treatments In The U.S.

- FDA recently approved Symfi Lo™, a three-drug single-tablet antiretroviral (ARV) regimen, and Cimduo™, a double combination, for HIV treatment

TheStreet Quant Rating: C+ (Hold)